# COSMIC-021 (NCT03170960)

> Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03170960
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Exelixis
- Conditions: Urothelial Carcinoma; Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Castration-resistant Prostate Cancer; Triple Negative Breast Cancer; Ovarian Cancer; Endometrial Cancer; Hepatocellular Carcinoma; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Colorectal Cancer; Head and Neck Cancer; Differentiated Thyroid Cancer; Lower Esophageal Cancer
- Interventions: cabozantinib; atezolizumab; cabozantinib; cabozantinib
- Enrollment: 914
- Primary outcome: Dose Escalation: MTD/Recommended Dose
- Primary outcome: Dose Expansion: ORR

## Indexed commentary on COSMIC-021 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 36
- Podcasts: 12
- YouTube: 7
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=cosmic-021-nct03170960

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03170960", "email": "<work email>"}; the inbox owner confirms by the emailed link.